Literature DB >> 20149758

Prostate gland edema after single-fraction high-dose rate brachytherapy before external beam radiation therapy.

Fabio L Cury1, Marie Duclos, Armen Aprikian, Horacio Patrocinio, Luis Souhami.   

Abstract

PURPOSE: High-dose rate brachytherapy (HDRB) is frequently used as a boost to external beam radiation therapy (EBRT) in prostate cancer patients. With the increasing use of small planning target volume margins in EBRT, prostatic edema induced by HDRB can be a contributing factor to geometric miss when HDRB is performed before or during EBRT. We assessed prostate gland volumetric change after single-fraction HDRB and its impact on definition of treatment volume for EBRT. METHODS AND MATERIALS: Thirty-one consecutive patients with intermediate-risk prostate cancer treated with single-fraction HDRB (10 Gy) combined with hypofractionated EBRT were analyzed. A second CT scan was performed 7 days after HDRB, and images were coregistered with the planning CT scan that contained the original clinical target volume (CTV). The post-HDRB prostate CTV volume was compared with the original CTV by a single observer.
RESULTS: All patients presented volumetric variation. In most cases (68%), the prostate increased in volume, whereas it decreased in 32%. The mean prostatic volume was 42.2 cc before HDRB and 43.6 cc after HDRB, representing a mean volume difference of 3.4%, ranging from -14.2% to 23.8% (p=0.756). This difference is the result of mean changes of 0.6mm (-6.1 to 6.6) in the anterior-posterior, 0.5mm (-5.5 to 3.0) in the lateral, and 0.2mm (-5.0 to 5.0) in the superior-inferior axes.
CONCLUSIONS: Although a nonsignificant volumetric change occurs after single-fraction HDRB, individual variations on specific axis could lead to important uncertainties during EBRT. (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20149758     DOI: 10.1016/j.brachy.2009.09.003

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  4 in total

1.  Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.

Authors:  Shoichi Fukuda; Yuji Seo; Hiroya Shiomi; Yuji Yamada; Toshiyuki Ogata; Masahiro Morimoto; Koji Konishi; Yasuo Yoshioka; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-06-23       Impact factor: 2.724

2.  Edema worsens target coverage in high-dose-rate interstitial brachytherapy of mobile tongue cancer: a report of two cases.

Authors:  Ken Yoshida; Hideya Yamazaki; Tadayuki Kotsuma; Hironori Akiyama; Tadashi Takenaka; Koji Masui; Yasuo Yoshioka; Yasuo Uesugi; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Takumi Arika; Eiichi Tanaka; Yoshifumi Narumi
Journal:  J Contemp Brachytherapy       Date:  2017-01-16

3.  Prostate volume and implant configuration during 48 hours of temporary prostate brachytherapy: limited effect of oedema.

Authors:  Anna M Dinkla; Bradley R Pieters; Kees Koedooder; Niek van Wieringen; Rob van der Laarse; Arjan Bel
Journal:  Radiat Oncol       Date:  2014-12-11       Impact factor: 3.481

4.  A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer.

Authors:  Ken Yoshida; Tadayuki Kotsuma; Hironori Akiyama; Hideya Yamazaki; Tadashi Takenaka; Koji Masui; Yutaka Tsujimoto; Naoya Murakami; Yasuo Uesugi; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Mio Nakata; Takumi Arika; Yuji Takaoka; Eiichi Tanaka; Nikolaos Tselis
Journal:  J Contemp Brachytherapy       Date:  2019-12-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.